Eledon Pharmaceuticals (ELDN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Eledon Pharmaceuticals (ELDN) is Neutral.

The composite score behind that read is -0.13, weighing +0.01 of bullish evidence against -0.28 bearish.

Eledon Pharmaceuticals last closed at $2.48, +2.48% on the session.

Against the IVW growth benchmark the position is +1.68% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

10 graded predictions for ELDN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Eledon Pharmaceuticals in the 11th percentile on return on equity, where 100 is best.

Eledon Pharmaceuticals is classified under Health Care / Biotechnology, with a market capitalisation of $196.65M.

StockMap tracks Eledon Pharmaceuticals as the 249th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Eledon Pharmaceuticals ranks 249th of 381 in the group, against a group median of -0.08.